Innovative treatments: revenues of the pharmaceutical industry France 2016

This statistic shows the results of a survey concerning the payment of dividends by the pharmaceutical industry thanks to the revenues of the innovative treatments reimbursed by the French Social Security in 2016. More than a third of respondents did not at all agree with the idea that the pharmaceutical industry pays dividends to its shareholders with the revenues of expensive innovative treatments reimbursed by Social Security.

Do you agree with the idea that it is normal for the pharmaceutical industry to pay dividends to its shareholders with the revenues of expensive innovative treatments reimbursed by Social Security? *

Characteristic	Share of respondents
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

March 2016

More information

Region

France

Survey time period

February 25 - 27, 2016

Number of respondents

1,004 respondents

Age group

15 years and older

Method of interview

Telephone interview

Supplementary notes

* The question was formulated by the source as follows: "The prices of some innovative drugs are rising. In France, for example, recently for hepatitis C, treatment at 40,000 euros has led to the selection of patients: it has only been delivered to the most serious cases.
For each of the following opinions, say: us if you strongly agree, tend to agree, tend to disagree or strongly disagree.
- It is normal for the pharmaceutical industry to pay dividends to its shareholders with income expensive innovative treatments reimbursed by Social Security. "

Open this statistic in...

French

Citation formats